Bovine spongiform encephalopathy threatens drugs in European UnionBMJ 1997; 315 doi: https://doi.org/10.1136/bmj.315.7105.426 (Published 16 August 1997) Cite this as: BMJ 1997;315:426
- Alan Earl-Slater, Senior lecturer in health economicsa
- a Keele University, Department of Medicines Management, Keele, Staffordshire ST5 5BG
Editor—While the debates about bovine spongiform encephalopathy periodically have a high profile in public health, food safety, and agricultural and political environments, the pharmaceutical environment is now becoming seriously entangled in the web of controversy. On 20 February this year the pharmaceutical council of the European parliament accepted the European Commission's proposed revisions to directive 75/18/EEC.
If the revisions are accepted by the European Union's Council of Ministers it will mean that drugs …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial